Drug Trial Radar · NCT07361874
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Mar 5, 2026
Primary completion
May 31, 2030
Study completion May 31, 2030
Sponsor
- Lead sponsor
- University of Texas Southwestern Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- First posted
- Jan 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to learn how two treatments-adrenalectomy (surgical removal of an adrenal gland) and semaglutide (a medication used for weight management)-affect insulin resistance and cortisol regulation in adults with mild autonomous cortisol secretion (MACS). The study will also learn how these treatments impact body composition, blood pressure, cholesterol, inflammation, muscle strength, and quality of life. The main questions the study aims to answer are: 1. Does adrenalectomy or semaglutide improve insulin resistance more in people with MACS? 2. How do these treatments change cortisol patterns and other cardiometabolic risk factors? 3. Do people with MACS respond differently to semaglutide compared to matched adults without MACS? 4. Among participants who enter the optional extension phase, are treatment-related changes maintained or further modified with longer-term treatment and follow-up? Participants will: 1. Receive either adrenalectomy or semaglutide if they have MACS, or semaglutide if they are matched controls 2. Complete clinic visits and phone visits 3. Undergo metabolic testing such as blood tests, urine steroid profiling, body composition scans, blood pressure monitoring, muscle strength testing, and questionnaires about health and well-being 4. If eligible, have the option to participate in an extension phase with continued treatment and follow-up through approximately 12 months
Conditions
- Mild Autonomous Cortisol Secretion (MACS)
- Autonomous Cortisol Secretion (ACS)
- Subclinical Cushing's
- Mild Autonomous Cortisol Excess
Interventions
Intervention 1: AdrenalectomyProcedure
Surgical removal of one adrenal gland performed by an endocrine surgeon following institutional standard-of-care practices. Includes postoperative monitoring for adrenal insufficiency and routine clinical follow-up.
Intervention 2: SemaglutideDrug
Once-weekly subcutaneous semaglutide administered according to FDA-approved titration for chronic weight management (0.25 mg to 2.4 mg weekly as tolerated). Participants receive training on injection technique, dose escalation, and safety monitoring.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Insulin Sensitivity (M-value), mg/kg/minTime frame: Baseline to Week 26
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.